Singapore's Sharpa Wins CES 2026 Innovation Award for Groundbreak AI Robotic Hand SharpaWave
SINGAPORE, Nov. 7, 2025 /PRNewswire/ -- Sharpa, a Singapore-based AI robotics company, announced that its flagship product, the dexterous robotic hand SharpaWave, has been named a CES 2026 Innovation Awards Honoree in the Robotics category....
ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
SUZHOU, China, Nov. 7, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key...
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES, Nov. 6, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense...
UTM Rises to Top 25 in QS Asia University Rankings 2026
JOHOR BAHRU, Malaysia, Nov. 5, 2025 /PRNewswire/ -- Universiti Teknologi Malaysia (UTM) continues its upward trajectory in the QS World University Rankings: Asia 2026, advancing to the 25th position — its highest regional placement to date. This...
Google and Dot Inc. Unite in a Strategic Partnership to Make Education More Inclusive
Google and Korean startup Dot Inc. have joined forces to advance education for blind and low-vision learners worldwide. SEOUL, South Korea, Nov. 4, 2025 /PRNewswire/ -- Google Asia Pacific and Dot Inc. have signed a strategic Memorandum of...
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product...
GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been...
Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
HONG KONG, Nov. 3, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer...
Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics
BEIJING, Oct. 28, 2025 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms at the 2025 Festival of Biologics in Basel. Over 2,000 biotech experts from 50...
Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology,...